Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive soft tissue cancer that occurs most often in pediatric and young adult patients. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Northwestern Mutual, through its Foundation, announced a class of scholars from its annual Childhood Cancer Scholarship Program for families affected by childhood cancer. The program provides scholarships to students affected by a diagnosis—either as survivors themselves or as siblings—enabling recipients to chase their dreams and transform their experience into purpose.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login